Breaking News Instant updates and real-time market news.

EIGR

Eiger BioPharmaceuticals

$13.60

-0.31 (-2.23%)

13:35
03/25/19
03/25
13:35
03/25/19
13:35

Eiger announces Phase 2 PREVENT study met primary efficacy endpoint

Eiger BioPharmaceuticals announced Phase 2 PREVENT study results in an oral presentation at ENDO 2019 in New Orleans. PREVENT is a multi-center, placebo-controlled, outpatient study investigating the safety and durability of 28-day dosing of avexitide subcutaneous injections in post-bariatric surgical patients who experience chronic, dangerously low, postprandial blood glucose levels, known as post-bariatric hypoglycemia or PBH. The primary efficacy endpoint of improved postprandial glucose nadir during mixed meal tolerance testing was achieved with statistical significance with avexitide 30 mg BID and 60 mg QD, with fewer participants requiring glycemic rescue during each of the active dosing regimens than during placebo dosing. The secondary endpoint of reduced postprandial insulin peak during MMTT was also statistically significant with avexitide 30 mg BID and 60 mg QD. Improvements in metabolic and clinical parameters were also monitored during each patients' daily routine in the outpatient setting and assessed by self-blood glucose monitoring, electronic diary, and continuous glucose monitoring. Patients experienced fewer episodes of hypoglycemia, severe hypoglycemia and a reduced rate of rescue during both dosing regimens of avexitide as compared to placebo. Rescue is defined as self- or third-party administration of oral or g-tube intake to prevent or treat hypoglycemia. Patients also demonstrated reductions in percent time in hypoglycemia during diurnal periods and number of episodes of hypoglycemia as measured by CGM. Avexitide was well-tolerated in this study. There were no treatment-related serious adverse events and no participant withdrawals. Adverse events were typically mild to moderate in severity. The most common adverse events were injection site bruising, nausea, and headache, all of which occurred with lower frequency during avexitide dosing periods than during the placebo dosing period.

EIGR Eiger BioPharmaceuticals
$13.60

-0.31 (-2.23%)

10/18/18
PIPR
10/18/18
NO CHANGE
Target $24
PIPR
Overweight
Eiger positive data opens HDV triple combo opportunity, says Piper Jaffray
Eiger BioPharmaceuticals last night announced positive end-of-treatment data from the Phase II study of InterferonLambda in hepatitis delta virus patients, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Importantly, Interferon-Lambda continued to show improved tolerability versus IFN-alfa, which should enable long-term dosing, the analyst contends. He believes the positive data opens up the opportunity for a hepatitis delta virus triple combo. Tenthoff reiterates an Overweight rating on shares of Eiger with a $24 price target.
12/19/18
BTIG
12/19/18
NO CHANGE
Target $47
BTIG
Buy
Eiger BioPharmaceuticals price target raised to $47 from $44 at BTIG
BTIG analyst Robert Hazlett raised his price target for Eiger BioPharmaceuticals to $47 from $44 after the company announced that FDA granted Lonafarnib Breakthrough Therapy for the treatment of Progeria and progeroid laminopathies. The analyst argues that Breakthrough status adds material regulatory and clinical validation to Lonafarnib's accelerated efforts in Progeria and should enable more rapid FDA review. An NDA filing istargeted for early 2019, he notes. Hazlett now models U.S. approval in Progeria in 2019, a Priority Review Voucher awarded and monetized around yearend 2019, and use in progeriod laminopathies, which modestly lifts NPV estimates. The analyst reiterates a Buy rating on the shares.
01/28/19
BARD
01/28/19
INITIATION
Target $47
BARD
Outperform
Eiger BioPharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar started Eiger BioPharmaceuticals with an Outperform rating and $47 price target. The company's hepatitis delta virus pipeline could transform the disease, with lonafarnib monotherapy in progeria can provide near-term, high EBIT margin revenue, Kumar tells investors in a research note.
01/29/19
01/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dell Technologies (DELL) initiated with an Outperform at Raymond James. 2. MasterCard (MA) and Visa (V) were initiated with a Buy at Jefferies. 3. Eiger BioPharmaceuticals (EIGR) initiated with an Outperform at Baird. 4. Arena Pharmaceuticals (ARNA) assumed with an Overweight at Cantor Fitzgerald. 5. Southern Copper (SCCO) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

01:55
12/12/19
12/12
01:55
12/12/19
01:55
General news
Asian Market Update: »

Asian Market Update:…

BILL

Bill.com

$0.00

(0.00%)

23:41
12/11/19
12/11
23:41
12/11/19
23:41
Syndicate
Bill.com 9.824M share IPO priced at $22.00 »

The deal size was raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FTSV

Forty Seven

$36.00

1.4 (4.05%)

23:39
12/11/19
12/11
23:39
12/11/19
23:39
Syndicate
Forty Seven 4.86M share Spot Secondary priced at $35.00 »

Morgan Stanley and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NCR

NCR Corp.

$32.60

0.16 (0.49%)

20:34
12/11/19
12/11
20:34
12/11/19
20:34
Hot Stocks
NCR enters consent decree to resolve claims related to Kalamazoo River matter »

NCR Corporation announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CIEN

Ciena

$35.45

0.75 (2.16%)

, LOVE

Lovesac

$14.49

0.05 (0.35%)

20:25
12/11/19
12/11
20:25
12/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CIEN

Ciena

$35.45

0.75 (2.16%)

LOVE

Lovesac

$14.49

0.05 (0.35%)

VERU

Veru

$2.47

0.17 (7.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 17

    Dec

  • 19

    Dec

CHEF

Chefs' Warehouse

$35.51

-0.06 (-0.17%)

20:24
12/11/19
12/11
20:24
12/11/19
20:24
Initiation
Chefs' Warehouse initiated at Piper Jaffray »

Chefs' Warehouse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HSBC

HSBC

$37.15

0.44 (1.20%)

20:13
12/11/19
12/11
20:13
12/11/19
20:13
Upgrade
HSBC rating change at BofA/Merrill »

HSBC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLCE

Children's Place

$54.36

-16.31 (-23.08%)

19:54
12/11/19
12/11
19:54
12/11/19
19:54
Downgrade
Children's Place rating change at Wedbush »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LVGO

Livongo Health

$27.55

1.48 (5.68%)

19:43
12/11/19
12/11
19:43
12/11/19
19:43
Syndicate
Livongo Health 2.78M share Secondary priced at $27.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CVX

Chevron

$116.22

-1.68 (-1.42%)

19:42
12/11/19
12/11
19:42
12/11/19
19:42
Periodicals
Chevron said to be close to approving Gulf of Mexico project, Bloomberg says »

Bloomberg's Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$233.00

0.03 (0.01%)

19:27
12/11/19
12/11
19:27
12/11/19
19:27
Hot Stocks
RH CEO sold 500,000 common shares of company from Dec 9 through Dec 11 »

RH announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$47.74

0.18 (0.38%)

19:17
12/11/19
12/11
19:17
12/11/19
19:17
Hot Stocks
Crowdstrike CFO sells 215K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 09

    Dec

GLD

SPDR Gold Shares

$138.94

0.98 (0.71%)

19:00
12/11/19
12/11
19:00
12/11/19
19:00
Hot Stocks
SPDR Gold Shares holdings rise to 886.22MT from 885.93MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$147.70

1.58 (1.08%)

, GOOG

Alphabet

$1,345.14

0.64 (0.05%)

18:59
12/11/19
12/11
18:59
12/11/19
18:59
Periodicals
Disney Plus was Google's most searched term in U.S. this year, TechCrunch says »

In the United States in…

DIS

Disney

$147.70

1.58 (1.08%)

GOOG

Alphabet

$1,345.14

0.64 (0.05%)

GOOGL

Alphabet Class A

$1,344.65

1.61 (0.12%)

AAPL

Apple

$270.71

2.09 (0.78%)

T

AT&T

$38.17

0.1 (0.26%)

NFLX

Netflix

$299.25

6.04 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

, FORM

FormFactor

$23.77

0.57 (2.46%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: DLH…

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

FORM

FormFactor

$23.77

0.57 (2.46%)

LULU

Lululemon

$233.31

3.75 (1.63%)

NX

Quanex

$19.72

0.68 (3.57%)

TLRD

Tailored Brands

$4.85

-0.42 (-7.97%)

NDSN

Nordson

$167.44

1.69 (1.02%)

MESA

Mesa Air

$9.25

0.17 (1.87%)

OXM

Oxford Industries

$74.07

-1.89 (-2.49%)

AKTS

Akoustis

$7.60

0.11 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 18

    Dec

TTD

Trade Desk

$250.44

0.13 (0.05%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Trade Desk CEO: We don't own any media »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$165.20

0.37 (0.22%)

18:45
12/11/19
12/11
18:45
12/11/19
18:45
Hot Stocks
Ferrari enters into new EUR 350M credit facility »

Ferrari announces that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIBT

RiceBran

$2.09

-0.105 (-4.79%)

18:43
12/11/19
12/11
18:43
12/11/19
18:43
Syndicate
RiceBran offers to sell common stock, no amount given »

Lake Street Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$151.00

2.27 (1.53%)

, TSLA

Tesla

$352.40

3.58 (1.03%)

18:42
12/11/19
12/11
18:42
12/11/19
18:42
Hot Stocks
VMware's Poonen: Our networking business is on fire »

In an interview on…

VMW

VMware

$151.00

2.27 (1.53%)

TSLA

Tesla

$352.40

3.58 (1.03%)

DELL

Dell Technologies

$47.73

0.37 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 07

    Jan

  • 08

    Jan

  • 09

    Jan

  • 27

    Feb

SMTC

Semtech

$47.36

0.48 (1.02%)

18:38
12/11/19
12/11
18:38
12/11/19
18:38
Hot Stocks
Semtech director sells 19.3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CS

Credit Suisse

$12.95

-0.115 (-0.88%)

18:29
12/11/19
12/11
18:29
12/11/19
18:29
Periodicals
Former Credit Suisse JV exec claims she was put under surveillance, WSJ says »

Colleen Graham, a former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PANW

Palo Alto Networks

$226.76

1.71 (0.76%)

18:22
12/11/19
12/11
18:22
12/11/19
18:22
Hot Stocks
Palo Alto Networks CEO: No systematic problem with our sales »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

PBYI

Puma Biotechnology

$8.71

0.24 (2.83%)

18:08
12/11/19
12/11
18:08
12/11/19
18:08
Hot Stocks
Puma Biotechnology presents Phase II results of neratinib in breast cancer »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTHX

G1 Therapeutics

$23.06

-0.18 (-0.77%)

18:05
12/11/19
12/11
18:05
12/11/19
18:05
Hot Stocks
G1 Therapeutics presents data from Phase 1b/2a trial of lerociclib at SABCS »

G1 Therapeutics reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NH

NantHealth

$0.86

-0.0225 (-2.54%)

18:01
12/11/19
12/11
18:01
12/11/19
18:01
Hot Stocks
NantHealth presents new breast cancer research findings at SABCS »

NantHealth announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.